University of Kent Spin-out Sirius Proteins Aims to Slash Protein Production Costs

A technology spin-out from the University of Kent is introducing a new method to lower the costs and complexity associated with recombinant protein production. The company, Sirius Proteins, leverages a specialized biological process to overcome traditional bottlenecks in the manufacturing of synthetic proteins.

Sirius Proteins utilizes Vesicle Nucleating Peptide (VNp) technology, developed by Professor Dan Mulvihill and his research team. The VNp system directs bacterial cells to package recombinant proteins into membrane-bound vesicles, which are then exported from the cell. This mechanism has been validated through a collaboration with the Science and Technology Facilities Council's Central Laser Facility (CLF), with findings published in the Journal of Extracellular Vesicles.

The Technical Challenge

Precision fermentation and lab-grown protein production are currently hampered by high capital expenditure and operational costs. A primary technical hurdle involves the production of proteins that are unstable, insoluble, or toxic to the bacteria used as production hosts. When these proteins accumulate inside the cell, they often cause cellular stress or fail to fold correctly, leading to low yields and expensive purification processes.

Sirius Proteins' VNp technology addresses these issues by sequestering the proteins into vesicles. By moving target proteins out of the bacterial cytoplasm and into exported vesicles, the system reduces toxicity to the host cell and improves the stability of the final product. This approach is particularly relevant for the production of complex proteins such as insulin.

Industry Implications

Reducing the cost of protein production is critical for the scalability of alternative proteins. If the cost of recombinant production drops significantly, alternative proteins can better compete with traditional animal-based sources on price and availability. Such a shift could have broad implications for global food security and significantly reduce the environmental footprint associated with industrial livestock farming.

Future Outlook

As Sirius Proteins moves from academic validation to commercial application, the industry will be watching for data on the scale of cost reductions achieved in industrial-sized bioreactors. While the VNp method shows promise in laboratory and collaborative settings, the next phase of development will determine if this approach can be standardized across a wider variety of protein types to disrupt the current high-cost manufacturing model.